FEFanny Eysert

Fanny Eysert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fanny Eysert has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Etude des mécanismes impliquant le facteur de risque génétique FERMT2 dans le métabolisme de l’APP et ses conséquences dans le processus physiopathologique de la maladie d’Alzheimer

    by Fanny Eysert

    La mise en place d’études d’association pangénomiques (GWAS) a permis une avancée majeure pour l’identification de nouveaux facteurs de susceptibilité génétique de la maladie d’Alzheimer (MA). En revanche, ces analyses réalisées sans a priori ne permettent pas de déterminer le rôle de ces gènes dans le processus physiopathologique de la MA. Dans ce contexte, seule la réalisation d’analyses dites « analyses post-GWAS » peut préciser les mécanismes moléculaires impliquant ces gènes. Le laboratoire a donc entrepris d’identifier quels sont, parmi les facteurs génétiques caractérisés par les GWAS, ceux dont la variation d’expression module le métabolisme de l’APP. De plus, notre modèle nous a permis d’étudier l’implication potentielle des micro-ARNs (miRs) dans la dérégulation de ces gènes.Dans ce contexte, nous avons pu montrer que le miR-4504, qui est surexprimé dans le cerveau des patients atteints de la MA par rapport aux témoins, diminue l’expression du gène FERMT2, facteur de susceptibilité génétique de la MA. Nos résultats montrent que cette sous-expression serait dépendante de la présence d’un variant (rs7143400) localisé dans le 3’UTR de FERMT2 qui entraîne alors une modulation du métabolisme de l’APP et une augmentation de la sécrétion du peptide Aβ.Dans ce projet, j’ai pu montrer que les effets de FERMT2 sur ce métabolisme nécessitent son interaction directe avec l’APP. De plus, l’utilisation du modèle de culture primaire de neurones en chambres micro-fluidiques m’a permis d’étudier les fonctions neuronales du complexe FERMT2/APP. J’ai ainsi pu identifier que cette interaction FERMT2/APP participe à la régulation de la croissance axonale et à la synaptogenèse. Finalement, nos analyses de la potentialisation à long terme dans le cerveau de souris, pour lesquelles une sous-expression de FERMT2 a été induite, montrent une diminution de la plasticité synaptique ; mécanisme pouvant être à l’origine de l’effet délétère de la baisse d’expression de FERMT2 dans les neurones et dans le processus physiopathologique de la MA.En conclusion, l’ensemble de ces résultats suggère le rôle du facteur de risque FERMT2, régulé par la présence du variant fonctionnel rs7143400 et du miR-4504 dans le processus physiopathologique de la MA en conduisant à des altérations synaptiques de façon dépendante de l’expression d’APP. Ce travail permettrait, à terme, de mieux comprendre le processus physiopathologique conduisant à la MA et de caractériser de nouveaux mécanismes impliqués dans le fonctionnement synaptique.

  • Open Access

    Inflammation-enhanced synapse-specific phagocytosis by adult APP microglia in a microfluidic neuron–microglia co-culture model

    by Dolores Siedlecki-Wullich, Anne-Marie Ayral, Lukas Iohan, Célia Lemeu, Valérie Buiche, Karine Blary, Julien Chapuis, Fanny Eysert, Delphine Beury, Myriam Delacre, et al.

    Microglia play a critical role in synapse remodeling and neuroinflammation, both of which are dysregulated in Alzheimer’s disease (AD). However, most in vitro models rely on neonatal or immortalized microglia, limiting their relevance to adult pathophysiological context. Here, we present a compartmentalized microfluidic co-culture platform that enables spatially controlled interactions between primary cortical neurons and adult microglia from wild-type (WT) and APP-transgenic mice. This system allows precise functional analysis of microglia–synapse interactions under defined inflammatory conditions. Upon lipopolysaccharide (LPS) stimulation, APP microglia exhibited exaggerated morphological activation, elevated IL-1β secretion, and selectively increased engulfment of synaptic material. In contrast, phagocytosis of non-specific substrates such as pHrodo™ Zymosan remained unchanged, suggesting a substrate-specific enhancement of microglial phagocytic activity. Blocking the complement receptor CD11b abolished the LPS-induced increase in synaptic uptake, confirming the role of complement-dependent pathways. Transcriptomic profiling revealed robust inflammatory responses in both genotypes, with selectively heightened expression of proinflammatory genes in APP microglia, consistent with a primed immune phenotype. Importantly, increased synaptic uptake occurred without measurable loss of global synaptic connectivity, highlighting the specificity and sensitivity of the system to detect microglial functional changes. This model captures genotype-dependent microglial reactivity (revealing phenotypes not fully captured by transcriptomic rofiling) and provides a physiologically relevant, tractable in vitro platform for dissecting microglial contributions to synaptic pathology in neurodegenerative disease.

  • Open Access

    Large extracellular vesicles containing mitochondria (EVMs) derived from Alzheimer’s disease cells harbor pathologic functional and molecular profiles and spread mitochondrial dysfunctions

    by Fanny Eysert, Véronique Legros, Anne-Sophie Gay, Delphine Debayle, Sandra Lacas-Gervais, Khouloud Kaidi, Guillaume Chevreux, Julien Lagarde, Fréderic Checler, Marie Sarazin, et al.

    In addition to small extracellular vesicles known as exosomes, cells release large extracellular vesicles containing mitochondria (EVMs). However, the molecular and functional characteristics of EVMs, as well as the impact of EVM secretion on the spreading of mitochondrial dysfunction between cells, remain unknown in the context of Alzheimer’s Disease (AD). Here, we provide an ultrastructural, biochemical, and functional characterization of EVMs isolated from cells expressing the amyloid precursor protein (APP) with the familial Swedish mutation (APPswe). We identified differential proteomic and lipidomic signatures in APPswe-derived EVMs compared to control EVMs and revealed a specific proteomic profile in EVMs isolated from conditioned media of fibroblasts from AD patients at the prodromal stage of the disease. Our findings show that APP-C terminal fragments (APP-CTFs) pathogenic accumulation in cells potentiates EVM secretion through the budding of the plasma membrane. We lastly demonstrated that APP-CTFs loaded EVMs are active carriers of dysfunctional mitochondria that transfer mitochondrial pathology to naïve control recipient cells.

  • Open Access

    Hampered AMPK-ULK1 cascade in Alzheimer’s disease (AD) instigates mitochondria dysfunctions and AD-related alterations that are alleviated by metformin

    by Arnaud Mary, Samantha Barale, Fanny Eysert, Audrey Valverde, Sandra Lacas-Gervais, Charlotte Bauer, Sabiha Eddarkaoui, Luc Buée, Valérie Buée-Scherrer, Frédéric Checler, et al.

    Background: Mitochondrial structure and function alterations are key pathological features in Alzheimer’s disease (AD) brains. The adenosine monophosphate-activated protein kinase (AMPK) and its downstream effector Unc-51 like autophagy activating kinase 1 (ULK1) represent a key node controlling mitochondria health, the alteration of which likely contribute to AD development. Methods: We designed this study to investigate AMPK-ULK1 activation state in post-mortem human sporadic AD brains, in 3xTgAD mice that recapitulate most of human AD features, and in neuronal cells expressing the amyloid precursor protein with the familial Swedish mutation (APPswe). We examined the impact of the pharmacological and genetic modulation of AMPK-ULK1 cascade on mitochondria structure and functions in APPswe cells. We evaluated the potential beneficial impact of AMPK-ULK1 activation by Metformin (Met) on mitochondria defects, as well as on early- and late-stage AD-related alterations in vivo and ex vivo . Results: At first, we show that AMPK-ULK1 cascade is defective in murine and human AD brains as well as in APPswe cells. We then report that Met administration to 3xTgAD mice alleviates the alterations of neuronal mitochondria structure and function and we consolidate these results in cells using both pharmacological and genetic tools to modulate AMPK-ULK1 cascade. In mice brains, Met reduces the early accumulation of APP C-terminal fragments (APP-CTFs) as well as the amyloid beta (Aβ) burden present in aged mice. Mechanistically, we show that Met increases the localization of APP-CTFs within cathepsin D-positive lysosomal compartments in vivo and enhances cathepsin D activity in vitro . The reduction of Aβ load by Met occurs through an increased recruitment of Iba1 + cells to Aβ plaques and an enhancement of the phagocytic activity of microglia. Accordingly, in symptomatic 3xTgAD mice, Met alleviates microgliosis and astrogliosis, modulates microglia morphology, reduces peripheral proinflammatory cytokines levels, and regulates the expression of a set of inflammatory genes. In addition, Met normalizes dendritic spines shape in organotypic hippocampal slice cultures modeling AD and improves learning performance of 3xTgAD mice. Conclusions: Our study demonstrates potential therapeutic benefits of targeting AMPK-ULK1 cascade to reverse both early and late AD-related alterations, deserving further investigation in fundamental research and in human clinical studies.

  • Open Access

    Mitochondria alterations in fibroblasts from sporadic Alzheimer’s disease (AD) patients correlate with AD-related clinical hallmarks

    by Fanny Eysert, Paula-Fernanda Kinoshita, Julien Lagarde, Sandra Lacas-Gervais, Laura Xicota, Guillaume Dorothée, Michel Bottlaender, Frédéric Checler, Marie-Claude Potier, Marie Sarazin, et al.

    INTRODUCTION: Mitochondria dysfunctions are key features in Alzheimer’s disease (AD). The occurrence of these disturbances in AD patient’s peripheral cells and their potential correlation with disease progression are under investigated. METHODS: We studied mitochondrial structure, function and mitophagy in fibroblasts including healthy volunteers and AD patients at the prodromal (AD-MCI) or demented (AD-D) stages. We carried out correlation studies with clinical cognitive scores, Aβ plaques burden and the accumulation of peripheral amyloid precursor protein C-terminal fragments (APP-CTFs). RESULTS: We unveiled progressive alteration of mitochondria structure as well as specific mitochondrial dysfunctions signatures in AD-MCI and AD-D fibroblasts and show defective mitophagy and autophagy linked to impaired lysosomal activity in AD-D fibroblasts. We reported on significant correlations of a subset of these dysfunctions with cognitive decline, AD-related clinical hallmarks and peripheral APP-CTFs accumulation. DISCUSSION: This study emphasizes the potential use of peripheral cells for investigating AD pathophysiology and likely diagnosis.

  • Open Access

    Primary brain cell infection by Toxoplasma gondii reveals the extent and dynamics of parasite differentiation and its impact on neuron biology

    by Thomas Mouveaux, Emmanuel Roger, Alioune Gueye, Fanny Eysert, Ludovic Huot, Benjamin Grenier-Boley, Jean-Charles Lambert, Mathieu Gissot

    Toxoplasma gondii is a eukaryotic parasite that forms latent cysts in the brain of immunocompetent individuals. The latent parasite infection of the immune-privileged central nervous system is linked to most complications. With no drug currently available to eliminate the latent cysts in the brain of infected hosts, the consequences of neurons' long-term infection are unknown. It has long been known that T. gondii specifically differentiates into a latent form (bradyzoite) in neurons, but how the infected neuron responds to the infection remains to be elucidated. We have established a new in vitro model resulting in the production of mature bradyzoite cysts in brain cells. Using dual, host and parasite RNA-seq, we characterized the dynamics of differentiation of the parasite, revealing the involvement of key pathways in this process. Moreover, we identified how the infected brain cells responded to the parasite infection revealing the drastic changes that take place. We showed that neuronal-specific pathways are strongly affected, with synapse signalling being particularly affected, especially glutamatergic synapse signalling. The establishment of this new in vitro model allows investigating both the dynamics of parasite differentiation and the specific response of neurons to long-term infection by this parasite.